Live
- Additional Collector Conducts Surprise Visit to Boys' Hostel in Wanaparthy
- Punjab hikes maximum state-agreed price for sugarcane, highest in country
- Centre okays PAN 2.0 project worth Rs 1,435 crore to transform taxpayer registration
- Punjab minister opens development projects of Rs 120 crore in Ludhiana
- Cabinet approves Atal Innovation Mission 2.0 with Rs 2,750 crore outlay
- Centre okays Rs 3,689cr investment for 2 hydro electric projects in Arunachal
- IPL 2025 Auction: 13-year-old Vaibhav Suryavanshi becomes youngest player to be signed in tournament's history
- About 62 lakh foreign tourists arrived in India in 8 months this year: Govt
- IPL 2025 Auction: Gujarat bag Sherfane Rutherford for Rs 2.60 cr; Kolkata grab Manish Pandey for Rs 75 lakh
- Assam CM meets Governor, cabinet expansion on the cards
Zydus Cadila receives USFDA nod for Fluphenazine Hydrochloride Tablets
Zydus Cadila receives USFDA nod for Fluphenazine Hydrochloride Tablets
Zydus Cadila on Saturday said it has received final approval from the US health regulator to market Fluphenazine Hydrochloride Tablets in the US
Zydus Cadila on Saturday said it has received final approval from the US health regulator to market Fluphenazine Hydrochloride Tablets in the US. This medication is used to treat symptoms of a certain type of mental/mood condition (schizophrenia).
The Company in a regulatory filing today said, the company has received approval from the US Food and Drug Administration (USFDA) to market Fluphenazine Hydrochloride Tablets in the strengths of 1 mg, 2.5 mg, 5 mg, and 10 mg (US RLD: Prolixin Tablets) in the US.
Fluphenazine belongs to a class of medications called phenothiazines and is also referred to as a neuroleptic.
The company said, the drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.
The group now has 318 approvals and has so far filed over 400 Abbreviated New Drug Applications (ANDAs) since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally.
